These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 25790041)

  • 1. Outcomes of ovarian germ cell tumors: ten years of experience at the Brazilian National Cancer Institute.
    Lopes da Silva J; Luiz Renna N; Paulino E; de Melo AC
    Int J Gynecol Cancer; 2015 Jun; 25(5):786-91. PubMed ID: 25790041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [BEP/VIP in children and adolescents with malignant non-testicular germ cell tumors. A comparison of the results of treatment of therapy studies MAKEI 83/86 and 89P/89].
    Göbel U; Calaminus G; Teske C; Bamberg M; Bökkerink JP; Haas RJ; Holschneider AM; Janka-Schaub G; Jürgens H; Mittler U
    Klin Padiatr; 1993; 205(4):231-40. PubMed ID: 7690864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term outcomes with intensive induction chemotherapy (carboplatin, bleomycin, vincristine and cisplatin/bleomycin, etoposide and cisplatin) and standard bleomycin, etoposide and cisplatin in poor prognosis germ cell tumours: A randomised phase II trial (ISRCTN53643604).
    Cafferty FH; White JD; Shamash J; Hennig I; Stenning SP; Huddart RA;
    Eur J Cancer; 2020 Mar; 127():139-149. PubMed ID: 32007714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcome of 3-day bleomycin, etoposide and cisplatin chemotherapeutic regimen for patients with malignant ovarian germ cell tumours: a Taiwanese Gynecologic Oncology Group study.
    Chen CA; Lin H; Weng CS; Wen KC; Lu CH; Chou HH; Huang YF; Kang CY; Ho CM; Yu MH; Chou CY
    Eur J Cancer; 2014 Dec; 50(18):3161-7. PubMed ID: 25459394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Late relapses (>2 years) in patients with stage I testicular germ cell tumors: predictive factors and survival.
    Fedyanin M; Tryakin A; Kanagavel D; Bulanov A; Burova A; Figurin K; Fainshtein I; Sergeev U; Zakharova T; Garin A; Tjulandin S
    Urol Oncol; 2013 May; 31(4):499-504. PubMed ID: 21803619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment of non-testicular germ cell tumors in children and adolescents with BEP and VIP: initial results of the MAKEI 89 therapy study].
    Göbel U; Bamberg M; Engert J; Gnekow AK; Haas HJ; Jürgens H; Kühl J; Lenard HG; Lumenta C; Niethammer D
    Klin Padiatr; 1991; 203(4):236-45. PubMed ID: 1719267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic analysis of Japanese men with metastatic germ cell tumors showing favorable response to bleomycin, etoposide and cisplatin as first-line chemotherapy.
    Kumano M; Miyake H; Hara I; Muramaki M; Takenaka A; Fujisawa M
    Hinyokika Kiyo; 2007 Dec; 53(12):851-6. PubMed ID: 18203521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of bleomycin, etoposide, and cisplatin for the treatment of advanced ovarian granulosa cell tumors.
    Pautier P; Gutierrez-Bonnaire M; Rey A; Sillet-Bach I; Chevreau C; Kerbrat P; Morice P; Duvillard P; Lhommé C
    Int J Gynecol Cancer; 2008; 18(3):446-52. PubMed ID: 18494093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paclitaxel+BEP (T-BEP) regimen as induction chemotherapy in poor prognosis patients with nonseminomatous germ cell tumors: a phase II study.
    Tryakin A; Fedyanin M; Kanagavel D; Fainstein I; Sergeev J; Polockij B; Matveev V; Zakharova T; Garin A; Tjulandin S
    Urology; 2011 Sep; 78(3):620-5. PubMed ID: 21764427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ovarian Cancer in Children and Adolescents: Treatment and Reproductive Outcomes.
    Chaopotong P; Therasakvichya S; Leelapatanadit C; Jaishuen A; Kuljarusnont S
    Asian Pac J Cancer Prev; 2015; 16(11):4787-90. PubMed ID: 26107241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II study of high-dose cisplatin, vinblastine, bleomycin, and etoposide (PVeBV regimen) in malignant nondysgerminomatous germ-cell tumors of the ovary.
    Culine S; Kattan J; Lhomme C; Duvillard P; Michel G; Castaigne D; Leclere J; Pico J; Droz JP
    Gynecol Oncol; 1994 Jul; 54(1):47-53. PubMed ID: 7517380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cisplatin, vinblastine, and bleomycin in advanced and recurrent ovarian germ-cell tumors. A trial of the Gynecologic Oncology Group.
    Williams SD; Blessing JA; Moore DH; Homesley HD; Adcock L
    Ann Intern Med; 1989 Jul; 111(1):22-7. PubMed ID: 2472080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Malignant ovarian germ cell tumors in pediatric patients: The AIEOP (Associazione Italiana Ematologia Oncologia Pediatrica) study.
    Terenziani M; Bisogno G; Boldrini R; Cecchetto G; Conte M; Boschetti L; De Pasquale MD; Biasoni D; Inserra A; Siracusa F; Basso ME; De Leonardis F; Di Pinto D; Barretta F; Spreafico F; D'Angelo P
    Pediatr Blood Cancer; 2017 Nov; 64(11):. PubMed ID: 28449306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic factors and efficacy of different chemotherapeutic regimens in patients with mediastinal nonseminomatous germ cell tumors.
    Fedyanin M; Tryakin A; Mosyakova Y; Pokataev I; Bulanov A; Zakharova T; Polockii B; Garin A; Tjulandin S
    J Cancer Res Clin Oncol; 2014 Feb; 140(2):311-8. PubMed ID: 24337455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intensive induction chemotherapy with C-BOP/BEP for intermediate- and poor-risk metastatic germ cell tumours (EORTC trial 30948).
    Fosså SD; Paluchowska B; Horwich A; Kaiser G; de Mulder PH; Koriakine O; van Oosterom AT; de Prijck L; Collette L; de Wit R;
    Br J Cancer; 2005 Nov; 93(11):1209-14. PubMed ID: 16251877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nondysgerminomatous ovarian tumors: clinical characteristics, treatment, and outcome. A case-controlled study.
    Ghaemmaghami F; Hasanzadeh M; Karimi Zarchi M; Fallahi A
    Int J Surg; 2008 Oct; 6(5):382-6. PubMed ID: 18715834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of ovarian germ cell tumors with a 3-day bleomycin, etoposide, and cisplatin regimen: a prospective multicenter study.
    Dimopoulos MA; Papadimitriou C; Hamilos G; Efstathiou E; Vlahos G; Rodolakis A; Aravantinos G; Kalofonos H; Kouroussis C; Gika D; Skarlos D; Bamias A
    Gynecol Oncol; 2004 Dec; 95(3):695-700. PubMed ID: 15581984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of malignant germ cell tumors of the ovary with bleomycin, etoposide, and cisplatin.
    Gershenson DM; Morris M; Cangir A; Kavanagh JJ; Stringer CA; Edwards CL; Silva EG; Wharton JT
    J Clin Oncol; 1990 Apr; 8(4):715-20. PubMed ID: 1690272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Favorable outcome of ovarian germ cell malignancies treated with cisplatin or carboplatin-based chemotherapy: a Hellenic Cooperative Oncology Group study.
    Dimopoulos MA; Papadopoulou M; Andreopoulou E; Papadimitriou C; Pavlidis N; Aravantinos G; Aspropotamitis A; Anagnostopoulos A; Fountzilas G; Michalas S; Pectacides D
    Gynecol Oncol; 1998 Jul; 70(1):70-4. PubMed ID: 9698477
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic factors and role of salvage surgery in chemorefractory ovarian germ cell malignancies: a study in Chinese patients.
    Li J; Yang W; Wu X
    Gynecol Oncol; 2007 Jun; 105(3):769-75. PubMed ID: 17459461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.